Issue of share options and total voting rights

RNS Number : 0334I

Yourgene Health PLC

12 April 2022

 

Yourgene Health plc

("Yourgene" or the "Company")

Issue of share options and total voting rights

Manchester, UK - 12 April 2022: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces the issuance of an aggregate 1,130,000 share options to 20 mostly overseas staff, for whom the Company's UK Share Incentive Plan is not applicable.  These new options are largely a substitution for 920,000 options which have lapsed in recent months due to the departures of three leavers in the UK.

The options are exercisable in three tranches over three financial years and are subject to certain performance conditions in line with the Company's share option scheme rules and previously issued share options. The exercise price of these options is 10 pence. The total number of share options now in issue is 59,828,471, representing c . 8.2% of the issued share capital or c.7.6% of the enlarged share capital, assuming no other issuance and that all of the currently issued options are exercised.

Total Voting Rights

For the purpose of the Disclosure and Transparency Rules, the current issued share capital of the Company comprises 727,100,243 ordinary shares of 0.1p each. The Company does not hold any ordinary shares in treasury. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules. 

This announcement contains inside information for the purposes of the UK Market Abuse Regulation.
The Directors of the Company take responsibility for this announcement.

Yourgene Health plc Lyn Rees, Chief Executive Officer	Tel: [phone] [e-mail]
Barry Hextall, Chief Financial Officer
Joanne Cross, Director of Marketing
Cairn Financial Advisers LLP (NOMAD)	Tel: [phone]
Liam Murray / James Caithie / Ludovico Lazzaretti
Singer Capital Markets (Joint Corporate Broker)	Tel: [phone]
Aubrey Powell / Tom Salvesen / George Tzimas
Stifel Nicolaus Europe Limited (Joint Corporate Broker)		Tel: [phone]
Nicholas Moore / Matthew Blawat / Ben Maddison
Walbrook PR Ltd (Media and Investor Relations)	Tel: [phone] or [e-mail]
Paul McManus / Lianne Applegarth	Mob: [phone] / Mob: [phone]

About Yourgene Health

Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science. 

Yourgene primarily develops, manufactures, and commercialises simple and accurate molecular diagnostic solutions, for reproductive health, precision medicine and now infectious diseases. The Group's flagship products include non-invasive prenatal tests (NIPT) for Down Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, and a recent extension into the oncology space with DPYD genotyping.

The launch of Yourgene Genomic Services has enabled Yourgene to offer a global laboratory service network equipped to be a full life-cycle partner for clinical, research and pharmaceutical organisations to support partners at the preclinical, clinical, and post-market stages to develop, manufacture, obtain regulatory approval and commercialise new products and services. In addition, Yourgene Genomic Services offers an NIPT and high throughput COVID testing service.

In August 2020, Yourgene acquired Coastal Genomics , Inc., a sample preparation technology company based in Vancouver, Canada, enabling the Company to extend its offering and IP portfolio in the DNA sample preparation sector. The acquisition increased Yourgene's geographical penetration into the US and Canada, supplementing existing coverage in the UK, Europe, MEA and Asia.

Yourgene Health is headquartered in Manchester, UK with offices in Taipei, Singapore, the US and Canada, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.

 

END

 

 

MSCKFLFFLZLFBBX